Kidney cancer drug study: why your genes matter
NCT ID NCT02404584
First seen Jan 09, 2026 · Last updated May 07, 2026 · Updated 16 times
Summary
This study looked at how the body processes the drug sunitinib in people with kidney cancer that has spread. Researchers measured drug levels in the blood and checked for genetic differences that might explain why levels vary. The goal was to understand why some patients get more or less of the drug, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Montpellier - Hôpital Saint-Eloi
Montpellier, 34295, France
-
CHRU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
-
Institut de Cancérologie du Gard (ICG)
Nîmes, 30029, France
Conditions
Explore the condition pages connected to this study.